Genomic and T cell repertoire biomarkers associated with malignant mesothelioma survival.

ABSTRACT:

Background

Malignant mesothelioma (MM) is an exceedingly rare tumor with poor prognosis due to the limited availability of effective treatment. Immunotherapy has emerged as a novel treatment approach for MM, but less than 40% of the patients benefit from it. Thus, it is necessary to identify accurate and effective biomarkers that can predict the overall survival (OS) and immunotherapy efficacy for MM.

Methods

DNA sequencing was used to identify the genomic landscape based on the data from 86 Chinese patients. T cell receptor (TCR) sequencing was used to characterize MM TCR repertoires of 28 patients between October 2016 and April 2023.

Results

Patients with TP53, NF2, or CDKN2A variants at the genomic level, as well as those exhibiting lower Shannon index (<6.637), lo

SUBMITTER: Nie M 

PROVIDER: S-EPMC11219294 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature